Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial

References

• Dore GJ, McDonald A, Li Y, et al. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 2003;17:1539–1545.
   PubMed Web of Science ®Google Scholar
• Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24(9):1243–1250.
   PubMed Web of Science ®Google Scholar
• Nightingale S, Winston A, Letendre S, et al. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014;13(11):1139–1151.
   PubMed Web of Science ®Google Scholar
• Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–1799.
   PubMed Web of Science ®Google Scholar
• Winston A, Duncombe C, Li PC, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis. 2010;50(6):920–929.
   PubMed Web of Science ®Google Scholar
• Winston A, Arenas-Pinto A, Stohr W, et al. Neurocognitive function in HIV infected patients on antiretroviral therapy. PLoS One. 2013;8(4):e61949.
   PubMed Web of Science ®Google Scholar
• Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65–70.
   PubMed Web of Science ®Google Scholar
• Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011;76(16):1403–1409.
   Web of Science ®Google Scholar
• Menard A, Montagnac C, Solas C, et al. Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe. AIDS. 2017;31(8):1201–1203.
   Web of Science ®Google Scholar
• Borghetti A, Baldin G, Capetti A, et al. Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. AIDS. 2017;31(3):457–459.
   PubMed Web of Science ®Google Scholar
• Bonfanti P, Madeddu G, Gulminetti R, et al. Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. AIDS. 2017;31(3):455–457.
   PubMed Web of Science ®Google Scholar
• Elzi L, Erb S, Furrer H, et al. Adverse events of raltegravir and dolutegravir. AIDS. 2017;31(13):1853–1858.
   PubMed Web of Science ®Google Scholar
• Lepik KJ, Yip B, Ulloa AC, et al. Adverse drug reactions to integrase strand transfer inhibitors. AIDS. 2018;32(7):903–912.
   Web of Science ®Google Scholar
• Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56–63.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Montoliu A, Miro JM, et al. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort. HIV Med. 2019;20(3):237–247.
   PubMed Web of Science ®Google Scholar
• Overton ET, Kauwe JS, Paul R, et al. Performances on the CogState and standard neuropsychological batteries among HIV patients without dementia. AIDS Behav. 2011;15(8):1902–1909.
   PubMed Web of Science ®Google Scholar
• Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–186.
   PubMed Web of Science ®Google Scholar
• Spitzer RL, Kroenke K, Williams JBW, Patient Health Questionnaire Study Group. Validity and utility of a self-report version of PRIME-MD: the PHQ Primary Care Study. Jama. 1999;282(18):1737–1744.
   PubMed Web of Science ®Google Scholar
• Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571.
   PubMed Web of Science ®Google Scholar
• Mora-Peris B, Bouliotis G, Ranjababu K, et al. Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals. AIDS. 2018;32(8):1007–1015.
   Web of Science ®Google Scholar
• Scott J, Underwood J, Garvey LJ, et al. A comparison of two post-processing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease. Br J Radiol. 2016;89(1060):20150979.
   Web of Science ®Google Scholar
• Mora-Peris B, Watson V, Vera JH, et al. Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. J Antimicrob Chemother. 2014;69(6):1642–1647.
   PubMed Web of Science ®Google Scholar
• Penchala SD, Fawcett S, Else L, et al. The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2016;1027:174–180.
   PubMed Web of Science ®Google Scholar
• Keegan MR, Chittiprol S, Letendre S, et al. Tryptophan metabolism and its relationship with depression and cognitive impairment among HIV-infected individuals. Int J Tryptophan Res. 2016;9:79–88.
   Web of Science ®Google Scholar
• Mora-Peris B, Winston A, Garvey L, et al. HIV-1 CNS in vitro infectivity models based on clinical CSF samples. J Antimicrob Chemother. 2016;71(1):235–243.
   Web of Science ®Google Scholar
• Yombi JC. Dolutegravir neuropsychiatric adverse events: specific drug effect or class effect. AIDS Rev. 2018;20(1):14–26.
   PubMed Web of Science ®Google Scholar
• Grill M, Gisslen M, Cinque P, et al. Kynurenine-tryptophan and phenylalanine-tyrosine levels in cerebrospinal fluid in HIV infection. Paper presented at: 19th Conference on Retroviruses and Opportunistic Infections. Seattle, USA, March 2012.
   Google Scholar
• Keegan MR, Winston A, Higgs C, et al. Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir. J Neurovirol. 2019;25(1):85–90.
   Web of Science ®Google Scholar
• Seyedsadjadi N, Berg J, Bilgin AA, et al. High protein intake is associated with low plasma NAD + levels in a healthy human cohort. PLoS One. 2018;13(8):e0201968.
   Web of Science ®Google Scholar
• Strasser B, Gostner JM, Fuchs D. Mood, food, and cognition: role of tryptophan and serotonin. Curr Opin Clin Nutr Metab Care. 2016;19(1):55–61.
   PubMed Web of Science ®Google Scholar
• Dahl V, Peterson J, Fuchs D, et al. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS. 2014;28(15):2251–2258.
   PubMed Web of Science ®Google Scholar
• Letendre SL, Mills AM, Tashima KT, et al. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis. 2014;59(7):1032–1037.
   PubMed Web of Science ®Google Scholar
• Elliot ER, Wang X, Singh S, et al. Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition. Clin Infect Dis. 2019;68(1):87–95.
   PubMed Web of Science ®Google Scholar